Location: Home /  About MGI

MGI Statement

Release date:2022-05-07Writer:MGIViews:4423Share

MGI is pleased that the jury verdict in the United States District Court for the District of Delaware supported all our claims, including:

 

1. Illumina willfully infringed U.S. Patent Nos. 9,222,132 and 10,662,473 owned by Complete Genomics, which is a US subsidiary of MGI.

2. The jury also found that Illumina's asserted claims of all three patents are invalid.

3. MGI was awarded approximately $334 million for past damages by Illumina.

 

The protection of intellectual property is very important to life science and biotechnology companies around the world, and it is also a value that MGI has always adhered to. MGI maintains its unwavering commitment to accelerating the industry development and providing our customers with "the right to another choice". Through our open and inclusive approach to innovation, we will work closely with industry partners to continue developing advanced genetic sequencing instruments to improve people's health.


For Chinese version statement: https://www.mgi-tech.com/news/464/


  • Hotline (Global)
    +86-4000-688-114
  • Email
    MGI-service@mgi-tech.com
  • Special Recommendations
  • *For research use only.

    Not for use in diagnostic procedures (except as specifically noted).
Copyright © 2024 All Rights Reserved MGI Tech Co., Ltd. Guangdong ICP 16117185Privacy PolicyLegal NoticesCookie Policy
Our use of cookies
We would like to use necessary cookies to improve your browsing experience and the quality of our website. We would also like to set analytics cookies and advertisement cookies that help us make improvements by measuring how you use our website. Detailed information about the use of cookies on this website and how you can control your consent can be found in our Cookie Policy and Privacy Policy.
Accept only strictly necessary cookiesAccept all cookies